Nagi Bioscience is thrilled to announce the successful closure of its Series A funding round co-led by Swisscanto and imec.xpand.
“This certification accredits that Nagi is fully ready to start scaling-up as commercial organization and to accomplish our mission of accelerating the transition to a new era of biological testing with our state-of-the-art technology.”
We are thrilled to announce the launch into the market of SydLab One: the first end-to-end automated high-content screening of substances on small organisms
Professing the transition to the new era of biological testing as our vision, being selected by the EIC Accelerator program is going to be crucial to make Nagi’s vision a reality.
Nagi Bioscience raises CHF 1.8 Million to accelerate its mission of setting a new standard for testing safety and efficacy of drugs and chemicals.